Vadillo C, Nieto MA, Romero-Bueno F, et al. - The present study was conducted to evaluate the clinical course in RA-related interstitial lung disease (RA-ILD) patients with and without rituximab (RTX). The impact of other variables was also assessed. Researchers conducted a longitudinal multicentre study in RA diagnosed with ILD, including a sum of 68 individuals between 2007 and 2018 in Madrid. Individuals were enrolled in a registry [pNEumology RhEumatology Autoinmune diseases (NEREA)] from the time of ILD diagnosis. The functional respiratory impairment (FI) was the main outcome, when there was a decline of ≥ 5% in the predicted forced vital capacity compared with the previous one. The results of this study indicated that RA-ILD individuals deteriorate over time, with the median time free of impairment being < 2 years. In comparison with other therapies, individuals exposed to RTX had a higher probability of remaining free of FI. In addition, other factors have also been distinguished.